retatrutide phase 2 trial new england journal of medicine approval: FDA status, clinical results, and when it could be available Retatrutide Phase 3: TRIUMPH Program

Both are GLP-1 medications that are FDA-approved for Type 2 diabetes and weight loss, but how they work differs Image content: This image is available to view online

This is the pathway responsible for the additional 3 to 5 percentage points of weight loss that Retatrutide achieves over dual-agonist compounds

This eliminates surprise charges and makes budgeting for treatment straightforward

14 Le says these challenges raise health equity questions

While the individual pathologies of MASLD and ALD are well-established, the specific pathophysiological mechanisms for MetALD development remain under active investigation and are currently considered hypothetical models that require further clinical validation

New England Journal of Medicine, 384(11), 989-1002